These associations show co-expression of both PVR and NT5E in approximately half of the GBM patient samples analyzed, showing that co-expression of CD155 and CD73 is prominent in GBM and dual-targeting of both antigens may be a promising approach to targeted immunotherapy. This evidence concerns the gene NT5E and glioblastoma.